Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $53.5 million.

  • Mirum Pharmaceuticals' Net Cash Flow rose 625.57% to $53.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.9 million, marking a year-over-year increase of 171.20%. This contributed to the annual value of -$62.1 million for FY2024, which is 139.19% down from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Net Cash Flow is $53.5 million, which was up 279.01% from $14.1 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Net Cash Flow high stood at $147.9 million for Q2 2023, and its period low was -$69.2 million during Q2 2024.
  • Moreover, its 3-year median value for Net Cash Flow was $6.1 million (2023), whereas its average is $13.8 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Net Cash Flow soared by 1,535.41% in 2023, and later slumped by 265.78% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Net Cash Flow (Quarterly) stood at $75.5 million in 2021, then slumped by 110.39% to -$7.8 million in 2022, then plummeted by 114.78% to -$16.8 million in 2023, then skyrocketed by 105.42% to $913,000 in 2024, then skyrocketed by 625.57% to $53.5 million in 2025.
  • Its Net Cash Flow was $53.5 million in Q3 2025, compared to $14.1 million in Q2 2025 and -$11.7 million in Q1 2025.